{
    "Case ID": "091704",
    "Different Crime": [
        {
            "Crime Name": "unknown",
            "Crime Type": "others",
            "patent_validity": [
                "'203 Patent is valid for Claims 5, 7, 29, 44, and 46",
                "Claims 1-4 are invalid"
            ],
            "relevant_statute": [
                "Patent Act"
            ],
            "evidence_presented": [
                "expert testimonies",
                "analysis of patent specifications",
                "evaluation of testing data"
            ],
            "infringement_analysis": [
                "Apotex's remaining bulk imatinib was exempt from infringement under regulatory use exemptions"
            ],
            "decision_reasoning": [
                "sound prediction was supported by prior art and disclosed data",
                "fulfilling utility requirements",
                "Disclosure included methods and results sufficient for skilled persons to practice the invention"
            ],
            "application_details": [
                "Teva and Apotex sought to invalidate Novartis's '203 Patent claiming selective kinase inhibitors"
            ],
            "conclusion_outcome": [
                "Most claims of the '203 Patent were upheld as valid"
            ],
            "specific_rule_applied": [
                "a patent must describe an invention that is both new and useful",
                "Utility can be demonstrated or soundly predicted based on factual basis, articulable reasoning, and adequate disclosure in the patent"
            ]
        }
    ]
}